Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.

Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, Jayakumaran G, Middha S, Zehir A, Donoghue MTA, You D, Viale A, Kemeny N, Segal NH, Stadler ZK, Varghese AM, Kundra R, Gao J, Syed A, Hyman DM, Vakiani E, Rosen N, Taylor BS, Ladanyi M, Berger MF, Solit DB, Shia J, Saltz L, Schultz N.

Cancer Cell. 2018 Jan 8;33(1):125-136.e3. doi: 10.1016/j.ccell.2017.12.004.

2.

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?

Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, Carneiro F, Oliveira C, Seruca R.

BMC Cancer. 2008 Sep 9;8:255. doi: 10.1186/1471-2407-8-255.

3.

Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.

Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF.

APMIS. 2013 Oct;121(10):954-66. doi: 10.1111/apm.12152. Epub 2013 Aug 29.

PMID:
23992303
4.

RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.

Bond CE, McKeone DM, Kalimutho M, Bettington ML, Pearson SA, Dumenil TD, Wockner LF, Burge M, Leggett BA, Whitehall VL.

Oncotarget. 2016 Oct 25;7(43):70589-70600. doi: 10.18632/oncotarget.12130.

5.

BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.

Nam SK, Yun S, Koh J, Kwak Y, Seo AN, Park KU, Kim DW, Kang SB, Kim WH, Lee HS.

PLoS One. 2016 Mar 18;11(3):e0151865. doi: 10.1371/journal.pone.0151865. eCollection 2016.

6.

RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.

Yan HHN, Lai JCW, Ho SL, Leung WK, Law WL, Lee JFY, Chan AKW, Tsui WY, Chan ASY, Lee BCH, Yue SSK, Man AHY, Clevers H, Yuen ST, Leung SY.

Gut. 2017 Sep;66(9):1645-1656. doi: 10.1136/gutjnl-2016-311849. Epub 2016 Jun 21.

PMID:
27329244
7.

BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.

Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D'Angelica MI, Vakiani E, Saltz LB.

Cancer. 2014 Aug 1;120(15):2316-24. doi: 10.1002/cncr.28729. Epub 2014 Apr 15.

8.

BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.

Chen J, Guo F, Shi X, Zhang L, Zhang A, Jin H, He Y.

BMC Cancer. 2014 Nov 3;14:802. doi: 10.1186/1471-2407-14-802.

9.

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.

Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, Harris R, James MD, Meade A, Jasani B, Adams RA, Kenny S, Kaplan R, Lambrechts D, Cheadle JP.

Clin Cancer Res. 2013 Aug 1;19(15):4104-13. doi: 10.1158/1078-0432.CCR-12-2581. Epub 2013 Jun 5.

10.

Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.

Corso G, Pascale V, Flauti G, Ferrara F, Marrelli D, Roviello F.

Eur J Hum Genet. 2013 Dec;21(12):1383-8. doi: 10.1038/ejhg.2013.66. Epub 2013 Apr 10.

11.

Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.

Scheel SK, Porzner M, Pfeiffer S, Ormanns S, Kirchner T, Jung A.

BMC Cancer. 2010 Aug 9;10:413. doi: 10.1186/1471-2407-10-413.

12.

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.

Palomba G, Doneddu V, Cossu A, Paliogiannis P, Manca A, Casula M, Colombino M, Lanzillo A, Defraia E, Pazzola A, Sanna G, Putzu C, Ortu S, Scartozzi M, Ionta MT, Baldino G, Sarobba G, Capelli F, Sedda T, Virdis L, Barca M, Gramignano G, Budroni M, Tanda F, Palmieri G.

J Transl Med. 2016 Oct 13;14(1):292.

13.

Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer.

Takahashi Y, Sugai T, Habano W, Ishida K, Eizuka M, Otsuka K, Sasaki A, Takayuki Matsumoto, Morikawa T, Unno M, Suzuki H.

Int J Cancer. 2016 Dec 1;139(11):2493-501. doi: 10.1002/ijc.30377. Erratum in: Int J Cancer. 2017 Jan 1;140(1):E1.

14.

Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.

Bisht S, Ahmad F, Sawaimoon S, Bhatia S, Das BR.

Med Oncol. 2014 Sep;31(9):124. doi: 10.1007/s12032-014-0124-3. Epub 2014 Jul 30.

PMID:
25073438
15.

Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, Vnencak-Jones CL.

Clin Colorectal Cancer. 2013 Sep;12(3):168-78. doi: 10.1016/j.clcc.2013.04.005. Epub 2013 Jun 14.

16.

AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.

Hechtman JF, Sadowska J, Huse JT, Borsu L, Yaeger R, Shia J, Vakiani E, Ladanyi M, Arcila ME.

Mol Cancer Res. 2015 Jun;13(6):1003-8. doi: 10.1158/1541-7786.MCR-15-0062-T. Epub 2015 Feb 24.

17.

Mutational profiling of colorectal cancers with microsatellite instability.

Lin EI, Tseng LH, Gocke CD, Reil S, Le DT, Azad NS, Eshleman JR.

Oncotarget. 2015 Dec 8;6(39):42334-44. doi: 10.18632/oncotarget.5997.

18.

Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.

Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem T, Cranston T, Danielsen H, Novelli M, Davidson B, Xu ZZ, Molloy P, Johnstone E, Holmes C, Midgley R, Kerr D, Sieber O, Tomlinson I.

J Pathol. 2013 Feb;229(3):441-8. doi: 10.1002/path.4139.

19.

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.

Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A.

Oncologist. 2016 Aug;21(8):988-94. doi: 10.1634/theoncologist.2016-0084. Epub 2016 Jul 5.

20.

DNA content analysis of colorectal cancer defines a distinct 'microsatellite and chromosome stable' group but does not predict response to radiotherapy.

Fadhil W, Kindle K, Jackson D, Zaitoun A, Lane N, Robins A, Ilyas M.

Int J Exp Pathol. 2014 Feb;95(1):16-23. doi: 10.1111/iep.12070.

Supplemental Content

Support Center